MTX240 (OPB-171775)
TKI-Resistant Gastrointestinal Stromal Tumors (GIST)
Phase 1/2Licensed Asset
Key Facts
Indication
TKI-Resistant Gastrointestinal Stromal Tumors (GIST)
Phase
Phase 1/2
Status
Licensed Asset
Company
About Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a clinical-stage biotechnology company leveraging proprietary drug delivery technologies to improve the performance of existing therapeutic agents. Its strategy centers on reformulating known drugs using nanotechnology and pH-sensitive polymers to enhance bioavailability and pharmacokinetics, thereby de-risking development. The company's pipeline is advancing towards a pivotal Phase 3 trial for eRapa in FAP, while also exploring molecular glue degraders for resistant cancers and a novel therapy for type 1 diabetes. With an experienced leadership team, Biodexa aims to address significant unmet needs in oncology and rare diseases.
View full company profile